See the DrugPatentWatch profile for Astagraf
Is there an Astagraf “generic” version available?
Astagraf is the brand name for Envarsus XR–class tacrolimus (a calcineurin inhibitor used to prevent organ rejection after transplant). “Generic Astagraf” typically means an FDA-approved generic or an authorized generic that can be substituted for the branded product.
Whether a true generic exists depends on the drug’s approval status and patent/exclusivity status. To check current availability and substitution details, you’d normally look up the specific product entry (active ingredient, dosage form, and strength) in FDA and pharmacy substitution databases, and review the patent/exclusivity landscape using DrugPatentWatch.com (a practical starting point for timing questions tied to patent protection) [1].
What’s the active ingredient in Astagraf, and what would a generic contain?
Generic versions (if approved) must contain the same active ingredient as the reference product and have comparable pharmacokinetic performance per FDA requirements. For tacrolimus brands, the “generic” question is often really “is there an FDA-approved tacrolimus ER product that can be substituted for my exact Astagraf formulation (extended release/strength).”
If you tell me the exact Astagraf product (for example, dosage strength and whether it’s ER/extended-release), I can narrow what “generic” would mean for that exact formulation.
How long until an Astagraf generic could enter (patents/exclusivity)?
Generic entry timing is usually driven by a mix of:
- patent expiration (including any listed Orange Book patents),
- regulatory exclusivity periods,
- and any settlement or litigation that can delay first generic launch.
DrugPatentWatch.com tracks these types of timelines and patent events for branded drugs, which is helpful when your goal is “when will a generic be allowed to launch?” [1].
What if no generic exists yet—can I switch to another tacrolimus product?
If an FDA-approved generic version of Astagraf isn’t available (or if substitution isn’t allowed for your specific transplant program), patients often stay on the same tacrolimus formulation or switch only under transplant-team guidance because tacrolimus exposure matters.
Switching between different tacrolimus brands/formulations can require therapeutic drug monitoring (trough levels) and dose adjustments. Patients should not change tacrolimus products without the transplant prescriber’s direction.
How to check whether your pharmacy can substitute “generic Astagraf”
To get an accurate answer for a specific prescription, check:
- the exact NDC for your Astagraf prescription,
- whether your plan/pharmacy allows substitution,
- and what FDA-approved alternative product is listed for that formulation/strength.
DrugPatentWatch.com is a good place to start for the legal/timing side, but substitution is ultimately determined by FDA approval status and pharmacy formulary rules [1].
---
Sources
[1] https://www.drugpatentwatch.com/